Biomedical Engineering Reference
In-Depth Information
100. van Loevezijn, A, Allen, JD, Schinkel, AH, and Koomen, GJ. 2001. Inhibition of BCRP-
mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. Bioorg Med Chem
Lett 11:29-32.
101. Woehlecke, H, Osada, H, Herrmann, A, and Lage, H. 2003. Reversal of breast cancer
resistance protein-mediated drug resistance by tryprostatin A. Int J Cancer 107:721-728.
102. de Bruin, M, Miyake, K, Litman, T, Robey, R, and Bates, SE. 1999. Reversal of resis-
tance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett
146:117-126.
103. Qadir, M, O'Loughlin, KL, Fricke, SM, Williamson, NA, Greco, WR, Minderman, H,
and Baer, MR. 2005. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
Clin Cancer Res 11:2320-2326.
104. Gupta, A, Dai, Y, Vethanayagam, RR, Hebert, MF, Thummel, KE, Unadkat, JD, Ross, DD,
and Mao, Q. 2006. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the
human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone
and topotecan. Cancer Chemother Pharmacol 1-10.
105. Imai, Y, Tsukahara, S, Ishikawa, E, Tsuruo, T, and Sugimoto, Y. 2002. Estrone and
17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
Jpn J Cancer Res 93:231-235.
106. Sugimoto, Y, Tsukahara, S, Imai, Y, Sugimoto, Y, Ueda, K, and Tsuruo, T. 2003. Reversal
of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and
agonists. Mol Cancer Ther 2:105-112.
107. Yanase, K, Tsukahara, S, Asada, S, Ishikawa, E, Imai, Y, and Sugimoto, Y. 2004. Gefitinib
reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther
3:1119-1125.
108. Nakamura, Y, Oka, M, Soda, H, Shiozawa, K, Yoshikawa, M, Itoh, A, Ikegami, Y, Tsu-
rutani, J, Nakatomi, K, Kitazaki, T, et al. 2005. Gefitinib (“Iressa,” ZD1839), an epi-
dermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance
protein/ABCG2-mediated drug resistance. Cancer Res 65:1541-1546.
109. Ozvegy-Laczka, C, Hegedus, T, Varady, G, Ujhelly, O, Schuetz, JD, Varadi, A, Keri,
G, Orfi, L, Nemet, K, and Sarkadi, B. 2004. High-affinity interaction of tyrosine
kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65:1485-
1495.
110. Houghton, PJ, Germain, GS, Harwood, FC, Schuetz, JD, Stewart, CF, Buchdunger, E, and
Traxler, P. 2004. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter
and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64:2333-2337.
111. Cooray, HC, Janvilisri, T, van Veen, HW, Hladky, SB, and Barrand, MA. 2004. Interaction
of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res
Commun 317:269-275.
112. Zhang, S, Yang, X, and Morris, ME. 2004. Flavonoids are inhibitors of breast cancer
resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65:1208-1216.
113. Imai, Y, Tsukahara, S, Asada, S, and Sugimoto, Y. 2004. Phytoestrogens/flavonoids re-
verse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res
64:4346-4352.
114. Zhang, S, Yang, X, Coburn, RA, and Morris, ME. 2005. Structure activity relationships
and quantitative structure activity relationships for the flavonoid-mediated inhibition of
breast cancer resistance protein. Biochem Pharmacol 70:627-639.
Search WWH ::
Custom Search